Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Nabriva Therapeutics AG - ADR    NBRV

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/19/2017 06/20/2017 06/21/2017 06/22/2017 06/23/2017 Date
9.12(c) 9.07(c) 9.31(c) 10.5(c) 10.55(c) Last
3 520 20 338 24 343 29 043 21 149 Volume
-0.87% -0.55% +2.65% +12.78% +0.48% Change
More quotes
Financials ($)
Sales 2017 5,38 M
EBIT 2017 -64,4 M
Net income 2017 -65,2 M
Finance 2017 155 M
Yield 2017 -
Sales 2018 5,45 M
EBIT 2018 -79,8 M
Net income 2018 -81,3 M
Debt 2018 21,6 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 24,5x
EV / Sales2018 56,6x
Capitalization 287 M
More Financials
Company
Nabriva Therapeutics AG is a clinical-stage biopharmaceutical company.It engages in the research and development of novel antibiotics to treat infections, with a focus on the pleuromutilin class of antibiotics.The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna,... 
More about the company
Surperformance© ratings of Nabriva Therapeutics AG -
Trading Rating : Investor Rating :
More Ratings
Latest news on NABRIVA THERAPEUTICS AG -
02:23p PFIZER : FDA To Discuss Mylotarg Again And Nabriva`s Pivotal Antibiotic Data
06/19 NABRIVA THERAPEUTICS AG : Regulation FD Disclosure, Financial Statements and Exh..
06/09 NABRIVA THERAPEUTICS AG : Other Events, Financial Statements and Exhibits (form ..
06/06 NABRIVA THERAPEUTICS : Announces Webcast of Analyst & Investor Day on June 19, 2..
06/05 Nabriva Therapeutics Announces Webcast of Analyst & Investor Day on June 19, ..
06/02 Nabriva Therapeutics to present data at ASM Microbe supporting ongoing Phase ..
05/31 NABRIVA THERAPEUTICS AG : Changes in Registrant's Certifying Accountant, Financi..
05/24 NABRIVA THERAPEUTICS : Commences Previously Announced Tender Offer Related to th..
05/23 NABRIVA THERAPEUTICS AG : Other Events, Financial Statements and Exhibits (form ..
05/23 Nabriva Commences Previously Announced Tender Offer Related to the Proposed R..
More news
Sector news : Biotechnology & Medical Research - NEC
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
06/23 FDA To Discuss Mylotarg Again And Nabriva's Pivotal Antibiotic Data
06/19 FDA OKs new antibiotic to fight ABSSSI
06/19 Nabriva Therapeutics (NBRV) Investor Presentation - Slideshow
05/10 Nabriva Therapeutics reports Q1 results
04/26 The Antimicrobial Resistance Crisis
Advertisement
Chart NABRIVA THERAPEUTICS AG -
Duration : Period :
Nabriva Therapeutics AG -  Technical Analysis Chart | NBRV | US62957M1045 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 16,4 $
Spread / Average Target 55%
Consensus details
Managers
NameTitle
Colin Broom Chief Executive Officer
Daniel D. Burgess Chairman-Supervisory Board
Gary L. Sender Chief Financial Officer
Elyse G. Seltzer Chief Medical Officer
Thomas Lembck Chief Information Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NABRIVA THERAPEUTICS A..77.01%287
INCYTE CORPORATION35.91%27 907
QUINTILES IMS HOLDINGS..19.50%19 657
LONZA GROUP27.12%16 010
CELLTRION, INC.--.--%12 252
ALKERMES PLC5.58%8 957
More Results